Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is also discussed.Â
The abstract entitled: ‘Novel Advances in Obesity‘ was presented at the European Society for Paediatric Endocrinology, 15-17 Sept, 2022.
Questions:
- What has been the impact of glucagon-like peptide 1 agonists on weight management? (0:18)
- What other emerging agents appear promising in the treatment of obesity? (4:00)
- What will be the future directions of obesity research? (7:27)
Disclosures: Uberto Pagotto has received honorarium from Bruno Pharma.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ESPE 2022
